C4 Therapeutics, Inc.
CCCC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001662579
No open-market purchases or sales by C4 Therapeutics, Inc. insiders were filed in the last 90 days; 147 institutions reported holding it in 13F filings for Q2 2026, worth $547.6M in total; no superinvestor holds it.
13F holders, Q3 2021
Institutional positions in C4 Therapeutics, Inc. as of Sep 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 113
- +7 vs. Q2 2021
- Shares held
- 34.5M
- +3.36M (+10.8%) vs. Q2 2021
- Total value
- $1.54B
- +$363.9M (+30.9%) vs. Q2 2021
- New holders
- 19
- 53 more added
- Sold out
- 12
- 20 more reduced
1 institution that held it in Q2 2021 haven't filed for Q3 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CCCC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 147 | $547.6M |
| Q1 2026 | 123 | $221.3M |
| Q4 2025 | 101 | $152.5M |
| Q3 2025 | 97 | $116.6M |
| Q2 2025 | 102 | $78.2M |
| Q1 2025 | 115 | $102.6M |
| Q4 2024 | 113 | $231.8M |
| Q3 2024 | 118 | $365.9M |
| Q2 2024 | 115 | $281.3M |
| Q1 2024 | 106 | $475.6M |
| Q4 2023 | 92 | $265.6M |
| Q3 2023 | 84 | $64.5M |
| Q2 2023 | 100 | $94.1M |
| Q1 2023 | 121 | $117.5M |
| Q4 2022 | 117 | $231.4M |
| Q3 2022 | 114 | $345.9M |
| Q2 2022 | 113 | $297.2M |
| Q1 2022 | 125 | $904.8M |
| Q4 2021 | 119 | $1.15B |
| Q3 2021 | 113 | $1.54B |
| Q2 2021 | 107 | $1.21B |
| Q1 2021 | 83 | $926.8M |
Institutions, Q3 2021
Shares, value and share of portfolio for each institution holding C4 Therapeutics, Inc.; share changes are against Q2 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Tower Research Capital LLC (TRC) | 2,824 | $126.0K | 0.00% | +1,680+146.9% | Added |
| Point72 Hong Kong Ltd | 1,343 | $60.0K | 0.00% | +197+17.2% | Added |
| Migdal Insurance & Financial Holdings Ltd. | 1,194 | $53.0K | 0.00% | +1,194 | New |
| O'Shaughnessy Asset Management, LLC | 1,037 | $46.0K | 0.00% | 00.0% | Unchanged |
| Nisa Investment Advisors, LLC | 690 | $31.0K | 0.00% | 00.0% | Unchanged |
| Piscataqua Savings Bank | 401 | $18.0K | 0.02% | 00.0% | Unchanged |
| Rockefeller Capital Management L.P. | 400 | $17.0K | 0.00% | +400 | New |
| Group One Trading, L.P. | 300 | $13.0K | 0.00% | +300 | New |
| Endurance Wealth Management, Inc. | 350 | $12.0K | 0.00% | 00.0% | Unchanged |
| TCI Wealth Advisors, Inc. | 106 | $5.00K | 0.00% | +34+47.2% | Added |
| Parallel Advisors, LLC | 106 | $5.00K | 0.00% | +106 | New |
| Signaturefd, LLC | 16 | $1.00K | 0.00% | +16 | New |
| Quadrant Capital Group LLC | 4 | $0 | 0.00% | +4 | New |
| Cormorant Asset Management, LP | 0 | $0 | 0.00% | −354,495−100.0% | Sold out |
| Maven Securities LTD | 0 | $0 | 0.00% | −231,925−100.0% | Sold out |
| Mizuho Securities Co. Ltd. | 0 | $0 | 0.00% | −169,392−100.0% | Sold out |
| Pinz Capital Management, LP | 0 | $0 | 0.00% | −163,458−100.0% | Sold out |
| Monashee Investment Management LLC | 0 | $0 | 0.00% | −135,000−100.0% | Sold out |
| Logos Global Management LP | 0 | $0 | 0.00% | −112,928−100.0% | Sold out |
| Stenahm Asset Managment Ltd | 0 | $0 | 0.00% | −80,500−100.0% | Sold out |
| Caas Capital Management LP | 0 | $0 | 0.00% | −63,383−100.0% | Sold out |
| Woodline Partners LP | 0 | $0 | 0.00% | −25,926−100.0% | Sold out |
| Jacobs Levy Equity Management, Inc | 0 | $0 | 0.00% | −23,413−100.0% | Sold out |
| Ikarian Capital, LLC | 0 | $0 | 0.00% | −17,600−100.0% | Sold out |
| JGP Global Gestao de Recursos Ltda. | 0 | $0 | 0.00% | −6,853−100.0% | Sold out |
| Pictet Asset Management Ltd | – | – | – | – | Not filed |